#Clinical Oncology Next Generation Sequencing Market Size
Explore tagged Tumblr posts
trendingreportz · 2 months ago
Text
Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)
Clinical Oncology Next Generation Sequencing Market Overview
Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 
Report Coverage
The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.
By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.
By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.
By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.
By End Use: Hospitals/Clinics, Laboratories and Research Labs.
By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).
Request Sample
Key Takeaways
The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.
Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.
The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.
Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.
Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type
Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.
Inquiry Before Buying
Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application
Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.
Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography
Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.
Schedule a Call
Clinical Oncology Next Generation Sequencing Market Drivers
Increasing Prevalence of Cancer:
Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.
Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:
In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.
Clinical Oncology Next Generation Sequencing Market Challenges
Major Regulatory Concerns & Lack Skilled Professionals:
Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.
Buy Now
Clinical Oncology Next Generation Sequencing Industry Outlook:
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.
Acquisitions/Product Launches:
In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation
In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.
In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.
0 notes
tbrcresearchreport · 2 years ago
Text
The Business Research Company offers clinical oncology next generation sequencing market research report 2023 with industry size, share, segments and market growth
1 note · View note
luckydige45 · 9 months ago
Text
According to a new report by nova one advisor, the global U.S. clinical oncology next generation sequencing market size surpassed USD 192.27 billion in 2023 and is anticipated to reach around USD 687.04 billion by 2032, expanding at a double digit CAGR of 15.2% from 2023 to 2032
0 notes
marketreports-blog · 1 year ago
Text
The U.S. clinical oncology next generation sequencing market size was estimated at USD 166.9 million in 2022 and is expected to surpass around USD 687.04 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 15.2% during the forecast period 2023 to 2032.
0 notes
neha24blog · 2 years ago
Text
U.S. Clinical Oncology Next Generation Sequencing Market Size Is Anticipated To Reach USD 1.53 Billion By 2024: Grand View Research Inc.
San Francisco, 27 April 2023: The Report U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow, By End Use, Regions, And Segment Forecasts 2018 To 2024 The U.S. clinical oncology next generation sequencing market is anticipated to reach USD 1.53…
Tumblr media
View On WordPress
0 notes
businessmarketreports · 2 days ago
Text
An Overview of Next Generation Sequencers Market: Trends and Insights
The Next-Generation Sequencers (NGS) market is witnessing rapid growth, driven by advancements in sequencing technology, declining costs, and increasing applications across healthcare, research, and agriculture. NGS enables high-throughput DNA sequencing, allowing for a more comprehensive analysis of genomes, transcriptomes, and epigenomes.
Tumblr media
Buy Full Report for More Insights on the Next Generation Sequencers Market Forecast Download a Free Sample Report
This market encompasses various components, including instruments, software, and reagents, catering to a wide array of end-users, such as hospitals, research institutes, and biotechnology firms.
1. Market Overview
Market Size and Growth: The NGS market has shown robust growth due to rising demand for genomic analysis in personalized medicine, cancer research, and genetic diagnostics. Increasing adoption in clinical settings, along with advancements in technology, has driven accessibility and expanded market reach.
Regional Trends: North America and Europe currently dominate the market due to high healthcare expenditures, advanced infrastructure, and a significant focus on research and development. Meanwhile, Asia-Pacific is emerging as a promising market due to rising healthcare investments and increasing adoption of genomic medicine.
Key Applications: The major applications for NGS include oncology, infectious disease diagnostics, reproductive health, and hereditary disease screening, along with applications in agriculture and environmental studies.
2. Key Trends in the NGS Market
Declining Sequencing Costs: The costs of sequencing have significantly dropped since the advent of NGS technologies. The "thousand-dollar genome" has become a reality, making genetic testing more affordable and accessible, particularly in research and clinical diagnostics.
Shift Towards Clinical Applications: There is a growing demand for NGS in clinical settings, particularly in oncology for tumor profiling, hereditary disease detection, and pharmacogenomics. Clinical applications are gaining traction due to their potential for precision medicine, helping tailor treatments to individual genetic profiles.
Focus on Cancer Research: Oncology remains a major application area for NGS, as it enables detailed cancer genome analysis, leading to better understanding of mutations and tumor behavior. This technology supports both research and diagnostic applications, fueling demand among pharmaceutical companies and research institutes focused on oncology.
Rise of Liquid Biopsies: NGS is widely used in liquid biopsies, which offer a non-invasive method for cancer detection and monitoring by analyzing cell-free DNA (cfDNA) from blood samples. Liquid biopsies are gaining popularity as they allow real-time monitoring of tumor progression and treatment efficacy, reducing the need for invasive procedures.
Emergence of Long-Read Sequencing: Long-read sequencing technologies, such as those offered by Pacific Biosciences and Oxford Nanopore, are gaining traction due to their ability to provide more comprehensive genomic insights. These technologies are particularly valuable in detecting structural variants and resolving complex genomic regions.
Development of Companion Diagnostics: NGS-based companion diagnostics, used to determine the efficacy and safety of a specific drug for a targeted patient group, are expanding. These diagnostics guide treatment decisions in oncology, particularly for identifying biomarkers associated with certain therapies.
3. Market Segmentation
By Product: The NGS market includes sequencers, software, consumables, and services. Consumables, including reagents and kits, constitute the largest segment due to repeated purchases. However, software solutions are gaining traction as data analysis and interpretation become more complex.
By Technology:
Whole Genome Sequencing (WGS): WGS provides a comprehensive view of the entire genome, making it suitable for research and complex disease studies.
Targeted Sequencing: Targeted sequencing is cost-effective and focuses on specific regions of interest, widely used in oncology and clinical diagnostics.
RNA Sequencing: RNA sequencing enables transcriptome analysis and is valuable in cancer research, gene expression studies, and drug discovery.
Exome Sequencing: Exome sequencing, which targets protein-coding regions, is a more affordable alternative to WGS and is commonly used for diagnosing genetic disorders.
By Application: The NGS market serves several applications, including oncology, infectious disease diagnosis, reproductive health, genetic screening, and forensic analysis. Oncology holds the largest share, while infectious disease applications, particularly in tracking pathogens and outbreaks, are rapidly growing.
By End User: The primary end-users include academic and research institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and government agencies. Hospitals and clinics are showing increasing demand as NGS technology moves from research into clinical diagnostics.
4. Key Drivers and Challenges
Drivers:
Increased Demand for Precision Medicine: The trend toward personalized medicine is a major driver, as NGS allows for tailored treatments based on genetic profiles, improving treatment outcomes.
Growing Investment in Genomic Research: Governments, healthcare institutions, and private companies are heavily investing in genomic research and infrastructure to support NGS applications across various fields.
Expansion of Genetic Screening Programs: Many countries are implementing large-scale genetic screening programs for early detection of genetic disorders and hereditary cancers, boosting demand for NGS.
Challenges:
Data Management and Analysis Complexity: The high volume of data generated by NGS requires advanced bioinformatics solutions for analysis, interpretation, and storage. This creates a need for skilled personnel and sophisticated software.
Regulatory and Ethical Concerns: The regulatory landscape for NGS is evolving, and concerns regarding data privacy and ethical issues are prevalent. Obtaining regulatory approval for clinical NGS applications can be time-consuming.
High Initial Investment: Although sequencing costs have decreased, the initial investment required for NGS platforms and bioinformatics infrastructure remains high, limiting adoption in resource-constrained regions.
5. Competitive Landscape
The NGS market is highly competitive, with established players as well as new entrants focusing on niche applications. Key players are investing in research and development, collaborations, and acquisitions to strengthen their market positions and expand product portfolios.
Illumina, Inc.: Illumina is the market leader, with a dominant position in sequencing instruments and consumables. Its sequencers, including the NovaSeq and NextSeq series, are widely used in research and clinical settings.
Thermo Fisher Scientific, Inc.: Known for its Ion Torrent platform, Thermo Fisher focuses on providing affordable, high-throughput sequencing solutions, with applications ranging from cancer research to infectious disease diagnostics.
Pacific Biosciences: PacBio specializes in long-read sequencing technology, particularly valuable for applications that require high accuracy in structural variant detection. Its Sequel system is popular among researchers in complex genomics.
Oxford Nanopore Technologies: Oxford Nanopore offers portable, real-time sequencing devices like the MinION and PromethION, which are particularly useful for field-based applications and rapid sequencing needs.
BGI Group: Based in China, BGI is a major player in genome sequencing services and provides a range of sequencers tailored for research and clinical applications. Its focus on affordability has helped it gain traction in emerging markets.
Qiagen N.V.: Qiagen provides NGS sample preparation and bioinformatics solutions, with a particular emphasis on clinical diagnostics. Its GeneReader NGS System is aimed at making NGS more accessible in clinical labs.
Agilent Technologies: Agilent offers NGS target enrichment and analysis solutions, focusing on workflows for oncology and hereditary disease testing.
6. Future Outlook
Advancements in Data Analysis Tools: Continued improvements in bioinformatics and artificial intelligence are expected to streamline data interpretation, making NGS more accessible to clinical users and reducing the time required for analysis.
Rise of Multi-Omics Approaches: Multi-omics, which combines genomics with proteomics, transcriptomics, and metabolomics, is expected to enhance the understanding of complex diseases. NGS will play a key role in integrating genomic data with other molecular insights.
Increased Focus on Rare Disease Research: NGS enables the identification of mutations associated with rare genetic disorders, facilitating research and development of targeted therapies. This area is likely to see continued growth, especially as pharmaceutical companies invest in precision medicine.
Expansion of Direct-to-Consumer (DTC) Testing: DTC genetic testing is gaining popularity, and as NGS becomes more affordable, companies may offer more comprehensive and affordable sequencing-based consumer tests.
Development of Point-of-Care Sequencing: Point-of-care NGS devices, offering rapid and portable sequencing capabilities, could find applications in emergency rooms and remote locations, particularly for infectious disease diagnosis.
Conclusion
The NGS market is positioned for substantial growth, driven by its expanding role in clinical diagnostics, advancements in sequencing technology, and increasing affordability. Applications in cancer research, infectious disease detection, and reproductive health are set to grow as the technology becomes more integrated into healthcare systems worldwide. However, challenges such as data complexity and regulatory hurdles will require ongoing innovation in bioinformatics and clear guidelines for clinical use. As technology advances, NGS has the potential to become a routine tool in personalized medicine, facilitating earlier diagnosis, better treatments, and improved patient outcomes across a range of medical fields.
0 notes
insightfulblogz · 7 days ago
Text
Cancer Biomarker Market Prominent Regions, Drivers, and Prospects 2032
Cancer biomarkers are biological molecules found in blood, other bodily fluids, or tissues that signify the presence of cancer. These biomarkers, which include proteins, gene mutations, and metabolites, are critical in diagnosing and monitoring cancer progression, predicting treatment responses, and personalizing therapies. By identifying specific biomarkers associated with different cancer types, healthcare providers can better understand the disease at a molecular level, enabling early detection and effective interventions. Cancer biomarkers have thus become essential tools in advancing precision medicine and improving patient outcomes.
The Cancer biomarkers market Size was valued at USD 22 billion in 2023, and is expected to reach USD 58.12 billion by 2032, and grow at a CAGR of 11.4% over the forecast period 2024-2032.
Future Scope
The future of cancer biomarkers lies in refining detection techniques, expanding the range of detectable biomarkers, and improving specificity. Research is currently focused on discovering novel biomarkers that can identify cancer at its earliest stages, even before symptoms arise. With the rise of liquid biopsy technologies, future advancements will allow clinicians to detect and monitor cancer non-invasively, providing ongoing insights into tumor genetics and mutation status. Additionally, multi-omics approaches combining genomics, proteomics, and metabolomics will enable more accurate diagnosis, prognosis, and treatment decisions, pushing cancer biomarkers to new heights in oncology care.
Trends
Emerging trends in cancer biomarkers include the development of digital pathology, AI-driven data analysis, and next-generation sequencing (NGS) to enhance biomarker discovery. There is also growing interest in immune-related biomarkers for cancer immunotherapy, as well as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) that provide real-time information on tumor dynamics. Personalized medicine initiatives are rapidly incorporating biomarker testing as standard practice in oncology, particularly for targeted therapies and immuno-oncology treatments. These trends reflect a significant shift toward personalized, data-driven approaches in cancer treatment.
Applications
Cancer biomarkers are widely used in early detection, diagnosis, and treatment monitoring. In early detection, they can identify cancer before symptoms develop, improving survival rates. For diagnosis, biomarkers help differentiate between cancer types and subtypes, guiding precise treatments. In therapeutic monitoring, biomarkers reveal the effectiveness of treatment, enabling adjustments to maximize patient response. Biomarkers also assist in drug development by identifying patients who are likely to benefit from new therapies, supporting personalized treatment plans and advancing clinical research.
Key Points
Cancer biomarkers are crucial in diagnosing, monitoring, and personalizing cancer treatment.
Future advancements will focus on non-invasive detection and expanding biomarker categories.
Trends include AI, digital pathology, and immune-related biomarkers.
Applications cover early detection, diagnosis, therapeutic monitoring, and drug development.
Get a Free Sample Copy of the Report: https://www.snsinsider.com/sample-request/3324 
Conclusion
Cancer biomarkers are revolutionizing oncology by offering a molecular-level understanding of cancer and enabling targeted, effective treatments. As technology and research continue to advance, the role of biomarkers will only strengthen, driving forward the development of non-invasive diagnostic methods and personalized therapies. With a focus on early detection and precision medicine, cancer biomarkers are helping healthcare providers deliver improved care and enhancing patient outcomes in the fight against cancer.
0 notes
farmacuticals · 9 days ago
Text
Competitive Landscape and Key Players in SNP Genotyping Market
The SNP genotyping and analysis market is witnessing remarkable growth, driven by advancements in genomics and an increasing focus on personalized medicine. SNP (single nucleotide polymorphism) genotyping identifies variations in a single nucleotide in a genome, aiding in the study of genetic predispositions to various diseases, drug responses, and genetic traits. This market includes the technologies, tools, and services used to genotype SNPs and conduct analysis, which has widespread applications in research, diagnostics, and drug development. The demand for SNP genotyping and analysis is particularly high in the fields of oncology, pharmacogenomics, and agricultural research, as it enables deeper insights into genetic variations and their impact on individual and population-level health outcomes.
The SNP Genotyping and Analysis Market Size was projected to reach $13.7 billion (USD billion) in 2022 based on MRFR analysis. It is anticipated that the market for SNP genotyping and analysis will increase from 15.11 billion USD in 2023 to 36.6 billion USD in 2032. During the forecast period (2024-2032), the SNP Genotyping and Analysis Market is anticipated to develop at a CAGR of approximately 10.33%.
SNP Genotyping and Analysis Market Share
The SNP genotyping and analysis market share is primarily held by leading companies like Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer state-of-the-art genotyping tools, reagents, and software solutions. These companies dominate the market due to their advanced platforms, broad research capabilities, and established partnerships with research and clinical institutions. New market entrants, however, are gaining a foothold by focusing on cost-effective, high-throughput genotyping solutions. The market share is also geographically diverse, with North America and Europe holding prominent shares due to extensive research funding and a large base of biotech companies, while Asia-Pacific is rapidly growing due to expanding healthcare and research infrastructure.
SNP Genotyping and Analysis Market Analysis
SNP genotyping and analysis market analysis indicates significant growth potential due to the rising prevalence of chronic diseases and the increasing demand for genomic data in clinical and research settings. The analysis also shows that innovations in high-throughput sequencing and bioinformatics are facilitating more efficient, cost-effective SNP genotyping. Technologies like microarray analysis and next-generation sequencing (NGS) are key drivers, providing rapid and accurate SNP data at a fraction of traditional costs. This market analysis highlights the impact of growing awareness of genetic testing among patients and healthcare providers, as well as increasing investments by governments and private entities in genomic research. The focus on personalized medicine, where treatments are tailored to individual genetic profiles, is expected to drive continuous demand in the SNP genotyping and analysis market.
SNP Genotyping and Analysis Market Trends
Key SNP genotyping and analysis market trends include the adoption of automation and AI in genomics. AI-powered data analysis helps interpret large datasets generated by SNP genotyping, enabling faster and more accurate insights into genetic associations. Another trend is the increased use of SNP genotyping in non-invasive prenatal testing (NIPT) and newborn screening, which has become an essential aspect of early disease diagnosis and prevention. Furthermore, the integration of genotyping and bioinformatics platforms enables researchers to conduct more comprehensive analyses, streamlining the identification of disease-related SNPs. The growing interest in consumer genomics, where individuals can gain insights into their ancestry and health risks through direct-to-consumer (DTC) testing kits, is also impacting the SNP genotyping and analysis market.
Reasons to Buy the Reports
Market Insights and Forecasts: Detailed projections on the SNP genotyping and analysis market, including future opportunities and growth drivers.
Competitive Landscape: Comprehensive information on market share and strategic positioning of key players, enabling informed decision-making.
Technological Trends: Insights into the latest technological advancements, such as AI integration, next-generation sequencing, and bioinformatics tools in SNP genotyping.
Regional Analysis: Regional breakdowns and growth potential insights to help investors and companies identify high-opportunity areas globally.
Personalized Medicine Focus: Analysis of the expanding role of SNP genotyping in personalized medicine, highlighting its applications in oncology, pharmacogenomics, and genetic testing.
Recent Developments
Recent developments in the SNP genotyping and analysis market reflect a focus on expanding applications and improving technology. In 2023, Thermo Fisher Scientific launched a new NGS-based genotyping platform designed for high-accuracy pharmacogenomic research, enhancing its utility in personalized medicine. Illumina introduced a cost-effective array platform targeting SNP genotyping for agricultural genomics, providing a tailored solution for crop and livestock breeding. Additionally, Bio-Rad Laboratories announced a strategic collaboration to integrate its genotyping software with AI-powered bioinformatics tools, improving analysis speed and accuracy. Advancements in point-of-care (POC) genotyping devices have also been significant, allowing for rapid SNP analysis in clinical settings and contributing to the increased demand in the SNP genotyping and analysis market.
Related repots:
medical equipment rental market
medical radiation shielding market
membrane filtration market
oral solid dosage pharmaceutical market
0 notes
insightsbyskyquest · 9 days ago
Text
Companion Diagnostics Market Size, Share, and Growth Analysis 2031
Tumblr media
The companion diagnostics market is a rapidly evolving segment of the healthcare industry, driven by advancements in personalized medicine and the growing need for targeted therapies. Companion diagnostics (CDx) are essential tools that help identify the appropriate patients for specific treatments, enhancing therapeutic efficacy and minimizing adverse effects. As the healthcare landscape continues to shift towards personalized medicine, the companion diagnostics market is poised for significant growth over the next decade.
As of 2023, the global companion diagnostics market was valued at approximately $7.37 billion. This market is expected to grow at a compound annual growth rate (CAGR) of around 11.4% from 2024 to 2031, potentially reaching $17.48 billion by the end of the forecast period. The increasing prevalence of chronic diseases, advancements in genomics, and the rising demand for personalized medicine are major factors driving this growth.
To Learn More About This Report, Request a Free Sample Copy - https://www.skyquestt.com/sample-request/companion-diagnostics-market
Key Market Segments
1. Technology Type
   - Polymerase Chain Reaction (PCR)
   - In Situ Hybridization (ISH)
   - Next-Generation Sequencing (NGS)
   - Immunohistochemistry (IHC)
2. Application
   - Oncology
   - Cardiovascular Diseases
   - Infectious Diseases
   - Neurological Disorders
3. End-User
   - Pharmaceutical Companies
   - Clinical Laboratories
   - Research Institutions
Regional Insights
North America currently holds the largest share of the companion diagnostics market, driven by a robust healthcare infrastructure, high levels of investment in R&D, and favorable reimbursement policies. Europe follows closely, with significant contributions from countries like Germany and the UK. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, fueled by increasing healthcare expenditures, rising awareness of personalized medicine, and expanding pharmaceutical sectors.
Top Player’s Company Profiles - Abbott, IDVet, F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., AniCell Biotech, Illumina, Inc., Guardant Health, Heska Corporation, Thermo Fisher Scientific Inc., BIOMERIEUX, NEOGEN Corporation, Zoetis Inc., QIAGEN, Myriad Genetics, Inc., Virbac SA
Growth Drivers
1. Rising Demand for Personalized Medicine: The shift from traditional one-size-fits-all treatments to personalized approaches is a significant driver of the companion diagnostics market. By identifying specific biomarkers, companion diagnostics enable tailored treatment plans.
2. Advancements in Genomic Technologies: The rapid advancement of genomic technologies, particularly next-generation sequencing, has revolutionized the development of companion diagnostics, allowing for more precise patient stratification.
3. Regulatory Support: Regulatory bodies, such as the FDA, have increasingly recognized the importance of companion diagnostics, leading to more streamlined approval processes and encouraging investment in this sector.
4. Growing Oncology Market: With cancer being one of the leading causes of death globally, the demand for effective targeted therapies and companion diagnostics in oncology is a significant growth driver.
Read Companion Diagnostics Market Report Today - https://www.skyquestt.com/report/companion-diagnostics-market
Future Outlook
The companion diagnostics market is expected to continue its upward trajectory, driven by innovation and increasing collaboration between diagnostic companies and pharmaceutical firms. The emergence of digital health technologies and artificial intelligence in diagnostics may further enhance market potential.
By 2031, the landscape of companion diagnostics will likely be characterized by:
- Greater Integration with Therapeutics: As more targeted therapies emerge; companion diagnostics will become integral to treatment protocols.
- Increased Adoption in Emerging Markets: The Asia-Pacific region will play a crucial role in the market's expansion, supported by growing healthcare investments. - Focus on Multi-Omics Approaches: The integration of genomics, proteomics, and metabolomics in companion diagnostics will enable more comprehensive patient assessments.
0 notes
prajwal-agale001 · 15 days ago
Text
NGS Market Insights: The Role of Sequencing in Precision Medicine
The global next-generation sequencing (NGS) market is on the verge of unprecedented growth, with an expected market size of $27.5 billion by 2030, according to the latest report from Meticulous Research®. With a compound annual growth rate (CAGR) of 15.8% from 2023 to 2030, the NGS industry is being propelled by a confluence of factors that promise to transform medical diagnostics, research, and pharmaceutical development.
NGS technology, which allows rapid sequencing of DNA and RNA, has revolutionized genomics research and medical diagnostics over the past decade. The decreasing cost of genome sequencing, coupled with technological advancements, is expanding the reach of NGS across multiple industries and applications. However, as this technology matures, the market faces challenges, including high system costs and ethical concerns, even as new opportunities in bioinformatics and genomic data management continue to emerge.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5040?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=23-10-24
Key Growth Drivers of the NGS Market
Rising Cancer Prevalence and the Role of NGS in Cancer Research The increasing prevalence of cancer is a significant factor driving the growth of the NGS market. NGS has emerged as a powerful tool in cancer research, enabling the identification of genetic mutations, better understanding of tumor biology, and development of precision medicine. By allowing the sequencing of entire genomes or specific genes linked to cancer, NGS helps researchers and clinicians design targeted therapies, improving patient outcomes.
Declining Costs of Genome Sequencing As the cost of genome sequencing continues to decrease, NGS is becoming more accessible to a wider range of researchers, clinicians, and healthcare providers. What once cost millions of dollars now costs a fraction of that amount, making it possible for institutions and even smaller research facilities to incorporate NGS into their diagnostic and research workflows. The reduced financial barriers are expected to increase adoption, particularly in oncology, rare genetic diseases, and reproductive health.
Technological Advancements in Sequencing Procedures Innovations in sequencing technology have played a pivotal role in enhancing the accuracy, speed, and cost-effectiveness of NGS. Advances such as sequencing-by-synthesis and nanopore sequencing are boosting the adoption of NGS by offering improved accuracy, lower error rates, and the ability to sequence longer DNA fragments. These advancements allow for more comprehensive genomic analysis and have applications in fields such as agriculture, infectious diseases, and personalized medicine.
Surge in Genome Mapping Programs and Pharmaceutical R&D Investments Governments and research institutions across the world are investing heavily in genome mapping initiatives, further driving the demand for NGS technologies. Additionally, the rising expenditure in pharmaceutical research and development is spurring the need for high-throughput sequencing to identify potential drug targets and biomarkers. NGS enables pharmaceutical companies to conduct comprehensive genomic studies that support drug discovery and development, particularly in the fields of oncology, infectious diseases, and immunology.
Favorable Regulatory and Reimbursement Landscape Regulatory agencies and insurance companies are becoming more supportive of NGS-based diagnostic tests, which is encouraging market growth. In the U.S., the Food and Drug Administration (FDA) has approved several NGS-based tests for clinical use, while favorable reimbursement policies for NGS diagnostics are making it easier for patients to access these advanced tests. This regulatory support is crucial in accelerating the adoption of NGS technologies, particularly in clinical settings.
Market Challenges Hindering Growth
Despite the immense potential of the NGS market, certain challenges must be addressed to ensure sustainable growth.
High Costs of NGS Systems and Consumables While the cost of sequencing has dramatically decreased, the upfront costs of NGS systems and consumables remain high. The ongoing need for specialized consumables such as reagents, sample preparation kits, and sequencing chips can strain the budgets of research institutions and clinical labs. This financial barrier is particularly acute for small- and medium-sized enterprises (SMEs) and academic institutions, which may struggle to afford the high cost of NGS infrastructure.
Alternative Technologies The availability of alternative genomic technologies such as microarrays and polymerase chain reaction (PCR) poses a challenge to the growth of the NGS market. These alternatives, which are often less expensive and more established, continue to be widely used for certain types of genetic testing. While NGS offers superior depth and accuracy, its cost and complexity can make it less appealing for some routine diagnostics.
Ethical and Legal Concerns The widespread use of NGS, particularly in diagnostic testing, raises significant ethical and legal issues. Concerns over privacy, data ownership, and the potential for discrimination based on genetic information must be carefully navigated by companies in the NGS space. These ethical dilemmas, along with regulatory and standardization challenges, are obstacles that need to be addressed to ensure the responsible adoption of NGS technologies.
Have specific research needs? Request a customized research report- https://www.meticulousresearch.com/request-sample-report/cp_id=5040?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=23-10-24
Emerging Opportunities in the NGS Market
Despite these challenges, the future of the NGS market is bright, with several emerging opportunities poised to drive continued growth.
Expansion of Bioinformatics and Genomic Data Management Solutions The vast amounts of data generated by NGS require sophisticated bioinformatics tools for analysis and interpretation. As the demand for NGS continues to rise, so too will the need for advanced genomic data management solutions that can store, process, and analyze this data efficiently. The integration of AI and machine learning into bioinformatics platforms is expected to further enhance the capabilities of NGS in clinical and research applications.
Government Initiatives and Large-Scale Genomic Sequencing Projects Many governments around the world are launching large-scale genomic sequencing projects aimed at improving healthcare outcomes, particularly in precision medicine. These initiatives, such as the U.K.'s 100,000 Genomes Project and the U.S.'s All of Us Research Program, are expected to drive demand for NGS technologies. The growing global focus on personalized medicine and genetic research provides ample opportunities for NGS market expansion.
Increasing Automation and Development of Portable Sequencing Technologies Automation is becoming a key trend in the NGS market, with manufacturers developing automated platforms that streamline the sequencing process and reduce the need for manual intervention. Additionally, the development of portable and handheld sequencing technologies is expected to make NGS more accessible in point-of-care settings and remote areas. These advancements are likely to expand the reach of NGS beyond traditional research and clinical settings.
Growing Partnerships and Collaborations Collaborations among NGS instrument manufacturers, pharmaceutical companies, and academic institutions are becoming increasingly common as companies seek to expand their product offerings and improve their competitive positioning. These partnerships are expected to accelerate technological innovation and drive the development of new NGS applications across various industries, from healthcare and agriculture to forensics and environmental science.
Get A Glimpse Inside: Request Sample Pages - https://www.meticulousresearch.com/download-sample-report/cp_id=5040?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=23-10-24
Key Market Segments and Regional Overview
The global NGS market is segmented by offering, sequencing type, technology, application, end-user, and geography. Each segment plays a critical role in the overall growth dynamics of the industry.
By Offering: The consumables segment is expected to dominate the NGS market in 2023, driven by the recurring need for reagents and kits in research and diagnostic workflows.
By Sequencing Type: Targeted genome sequencing is projected to capture the largest share of the market due to its cost-effective nature and application in oncology and genetic research.
By Technology: Sequencing-by-synthesis is expected to lead the market in 2023, primarily due to its high accuracy and reliability in DNA sequencing.
By Application: The research and other applications segment, which includes drug discovery and agriculture, is set to hold the largest market share, fueled by the increasing use of NGS in genetic research.
By End-User: Pharmaceutical and biotechnology companies are expected to account for the largest share of the market, as NGS plays a crucial role in drug development and precision medicine.
Regional Overview: North America is forecasted to lead the global NGS market in 2023, driven by strong R&D investment, the presence of key market players, and favorable regulatory policies.
Conclusion
The global next-generation sequencing market is on a robust growth trajectory, fueled by technological innovations, declining costs, and increasing applications across multiple industries. As governments, research institutions, and private companies continue to invest in genomics, the demand for NGS is set to rise, paving the way for breakthroughs in precision medicine, cancer research, and beyond. However, challenges such as cost barriers, ethical concerns, and the need for skilled professionals must be addressed to fully realize the potential of this transformative technology.
Read Full Report - https://www.meticulousresearch.com/product/next-generation-sequencing-market-5040
Contact Us: Meticulous Research® Email- [email protected] Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
0 notes
deshpandeisha · 1 month ago
Text
Understanding the Cancer Microbiome: A New Frontier in Oncology
The global cancer microbiome market size was USD 222.79 Million in 2022 and is expected to register a steady revenue CAGR of 19.9% during the forecast period, according to latest analysis by Emergen Research. Rising prevalence of cancer is a major factor driving market revenue growth. Microbiome is a collection of bacteria that live in and on human body, which have potential to affect initiation, progression, and treatment response of cancer, including cancer immunotherapy.
Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1768
Competitive Terrain:
The global Cancer Microbiome industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
The leading market contenders listed in the report are:
CD Genomics, Eurofins Scientific, Illumina, Inc., Prescient Medicine Holdings, Inc., Micronoma Inc., Novogene Co., Ltd., Oxford Nanopore Technologies plc., Pacific Biosciences of California, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Cancer Microbiome market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Cancer Microbiome market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Cancer Microbiome market.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1768
Market Segmentations of the Cancer Microbiome Market
This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Cancer Microbiome market on the basis of product, application, and region:
Segments Covered in this report are:
Techniques Outlook (Revenue, USD Million; 2019-2032)
Next Generation Sequencing
Polymerase Chain Reaction
Others
End-use Outlook (Revenue, USD Million; 2019-2032)
Hospitals
Clinic  
Others
Regional Outlook (Revenue, USD Million; 2019–2032)
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of Middle East & Africa
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/cancer-microbiome-market
Major Geographies Analyzed in the Report:
North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
ToC of the report:
Chapter 1: Market overview and scope
Chapter 2: Market outlook
Chapter 3: Impact analysis of COVID-19 pandemic
Chapter 4: Competitive Landscape
Chapter 5: Drivers, Constraints, Opportunities, Limitations
Chapter 6: Key manufacturers of the industry
Chapter 7: Regional analysis
Chapter 8: Market segmentation based on type applications
Chapter 9: Current and Future Trends
Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1768
0 notes
health-views-updates · 1 month ago
Text
NGS based RNA Sequencing Market Technology Growth, Supply Demand and Analysis By Types 2024-2032
The global Next-Generation Sequencing (NGS)-based RNA sequencing market is positioned for robust growth, with the market size valued at USD 2.9 billion in 2023 and projected to reach USD 12.1 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 17.1% over the forecast period from 2024 to 2032, driven by advancements in genomics research, precision medicine, and rising demand for RNA-based diagnostics and therapeutics.
NGS-based RNA sequencing is a powerful tool for studying gene expression, transcriptome profiling, and identifying novel RNA sequences. It provides unparalleled insight into the mechanisms of gene regulation, disease progression, and therapeutic targets, making it indispensable in both research and clinical settings.
Get a Sample Report@ https://www.snsinsider.com/sample-request/4554
Key Market Drivers
Advancements in Genomics and Transcriptomics Research: The rapid advancements in genomics research, coupled with the decreasing costs of sequencing technologies, are driving the adoption of NGS-based RNA sequencing. These advancements have revolutionized how scientists study gene expression, alternative splicing, and RNA editing, leading to breakthroughs in areas such as oncology, neurology, and immunology. The technology’s ability to provide high-resolution data on the transcriptome has fueled its widespread adoption in both academic research and pharmaceutical R&D.
Growing Application in Precision Medicine: Precision medicine, which aims to tailor treatments to individual genetic profiles, is another major driver of the market. NGS-based RNA sequencing allows for the comprehensive profiling of patients' transcriptomes, identifying specific biomarkers and therapeutic targets. This personalized approach is particularly valuable in cancer treatment, where RNA sequencing is used to identify mutations and gene fusions that can guide the selection of targeted therapies.
Rising Demand for RNA-Based Therapeutics and Vaccines: The success of mRNA vaccines during the COVID-19 pandemic has sparked increased interest in RNA-based therapeutics and vaccines. RNA sequencing plays a critical role in the development and optimization of these treatments, allowing researchers to study RNA expression patterns and develop effective interventions. The growing focus on RNA-based drug development is expected to drive further demand for NGS-based RNA sequencing.
Technological Innovations and Cost Reduction: Continuous innovations in sequencing technology, data analysis tools, and bioinformatics are making NGS-based RNA sequencing more accessible and cost-effective. New platforms that offer higher throughput, improved accuracy, and reduced turnaround times are enabling broader adoption across various research and clinical applications. As sequencing costs continue to decline, more institutions are expected to integrate NGS into their workflows, further driving market growth.
Expansion of RNA Sequencing in Clinical Diagnostics: RNA sequencing is increasingly being utilized in clinical diagnostics, particularly for cancer and rare genetic diseases. The technology enables the identification of gene expression changes, RNA fusions, and novel transcripts, which can be critical for diagnosing and stratifying patients based on their molecular profiles. As more RNA-based diagnostic tests receive regulatory approval, the demand for NGS-based RNA sequencing in clinical laboratories is expected to rise significantly.
Challenges and Opportunities
Despite its promising outlook, the NGS-based RNA sequencing market faces challenges such as the complexity of data interpretation, the need for advanced bioinformatics tools, and the integration of large-scale sequencing data into clinical workflows. Additionally, the high initial investment in sequencing infrastructure may pose barriers for smaller institutions.
However, these challenges are creating opportunities for innovation, particularly in the development of user-friendly bioinformatics platforms and cloud-based data analysis solutions. Collaborations between sequencing companies, software developers, and healthcare providers are expected to streamline the use of RNA sequencing in clinical settings, making it more accessible and scalable.
Regional Insights
North America holds the largest share of the NGS-based RNA sequencing market, driven by strong research funding, the presence of leading biotechnology companies, and the widespread adoption of precision medicine. The United States, in particular, has seen rapid advancements in cancer genomics and RNA therapeutics, fueling demand for RNA sequencing technologies.
Europe follows closely, with significant investments in genomic research and growing demand for RNA sequencing in both academic and clinical settings. The Asia-Pacific region is expected to experience the highest growth rate over the forecast period, supported by increasing healthcare investments, expanding research infrastructure, and the adoption of advanced sequencing technologies in countries like China, Japan, and India.
Future Outlook
The future of the NGS-based RNA sequencing market looks highly promising, with continued advancements in genomics, transcriptomics, and personalized medicine driving demand. As technology evolves and costs decline, RNA sequencing will become an integral tool in diagnosing, treating, and understanding complex diseases at the molecular level.
The market is set to expand rapidly, growing from USD 2.9 billion in 2023 to USD 12.1 billion by 2032, with a projected CAGR of 17.1% over the forecast period. As the integration of RNA sequencing into clinical practice accelerates, it will unlock new opportunities for innovation in healthcare, research, and drug development.
In conclusion, the NGS-based RNA sequencing market is poised for significant growth as technological advancements, rising applications in precision medicine, and increasing demand for RNA-based diagnostics and therapeutics reshape the landscape of healthcare and life sciences.
Other Trending Reports
Functional Endoscopic Sinus Surgery Market Share
Artificial Intelligence in Healthcare Market Share
Radiotherapy Market Share
Nicotine Replacement Therapy Market Share
0 notes
amrutatbrc1 · 2 months ago
Text
Clinical Oncology Next Generation Sequencing Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033
The clinical oncology next generation sequencing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Tumblr media
Clinical Oncology Next Generation Sequencing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size - The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.45 billion in 2023 to $0.52 billion in 2024 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.
The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Market Drivers - The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next-generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.9 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the growth of the clinical oncology next-generation sequencing market.
The clinical oncology next generation sequencing market covered in this report is segmented –
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing 2) By Application: Screening, Companion Diagnostics, Other Diagnostics 3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories
Get an inside scoop of the clinical oncology next generation sequencing market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp
Regional Insights - North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies - Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
Table of Contents 1. Executive Summary 2. Clinical Oncology Next Generation Sequencing Market Report Structure 3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies 4. Clinical Oncology Next Generation Sequencing Market – Macro Economic Scenario 5. Clinical Oncology Next Generation Sequencing Market Size And Growth ….. 27. Clinical Oncology Next Generation Sequencing Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
0 notes
chetanagblog · 2 months ago
Text
https://www.maximizemarketresearch.com/market-report/clinical-oncology-next-generation-sequencing-market/100383/
The Clinical Oncology Next-Generation Sequencing Market size was valued at USD 9.49 Billion in 2023 and the total Clinical Oncology Next-Generation Sequencing revenue is expected to grow at a CAGR of 20.7 % from 2024 to 2030, reaching nearly USD 35.42 Billion by 2030.
0 notes
marketreports-blog · 1 year ago
Text
The U.S. clinical oncology next generation sequencing market size was estimated at USD 166.9 million in 2022 and is expected to surpass around USD 687.04 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 15.2% during the forecast period 2023 to 2032.
0 notes
new-market-news · 2 months ago
Text
Companion Diagnostic Market Key Players, Dynamics & Latest Trades Report to 2032
Companion Diagnostic Market Report has recently added by Value Market Research, this surveillance report establishing the facts based on current scenarios, historical records from 2023 to future forecast upto 2032. This report explicit data of various outlook such as market share, size, growth rates, and industry opportunities and offering an economical advantage for business success. It furnish the 360-degree overview of the competitive landscape of the global industries. Porter’s Five Forces Model analysis has been used to understand the industry’s structure, strength, weaknesses, opportunities, threats and challenges in front of the businesses.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the companion diagnostics market include Abbott Laboratories Molecular, Inc., Agilent, ARUP Laboratories, Inc., BioMerieux SA, Danaher Corporation. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Get more information on "Global Companion Diagnostics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/companion-diagnostic-market/download-sample
Market Dynamics
Companion diagnostics are a crucial part of personalized medicine and will likely continue to rapidly increase in the number of disease areas. The next generation of drugs has to be safer and more efficacious. Companion diagnostics are one of the tools that can generate this information and make it available to drug developers. Escalating activities of drug discovery and vaccine development will be driving the market growth. Oncology is a segment of major focus and will remain at the forefront for the foreseeable future. Companion diagnostic play a major role in oncology research and has revolutionized the treatment of cancer by allowing doctors to adjust drug therapy to achieve better clinical results.  However, the high cost and uncertain reimbursement scenario in a different region are hampering the growth of the market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of companion diagnostics.
Browse Global Companion Diagnostics Market Research Report with detailed TOC at https://www.valuemarketresearch.com/report/companion-diagnostic-market
Market Segmentation
The entire companion diagnostics market has been sub-categorized into technology type, and indication. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Technology Type
Immunohistochemistry
Polymerase Chain Reaction
Next Generation Sequencing
In Situ Hybridization
Others
By Indication
Oncology
Neurology
Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for companion diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Purchase Complete Global Companion Diagnostics Market Research Report at https://www.valuemarketresearch.com/contact/companion-diagnostic-market/buy-now
About Us:
Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information.
We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.
Contact:
Value Market Research
UG-203, Gera Imperium Rise,
Wipro Circle Metro Station, Hinjawadi, Pune – 411057
Maharashtra, INDIA.
Tel: +1-888-294-1147
Website: https://www.valuemarketresearch.com
1 note · View note